Expert comment: landmark plans to accelerate rare disease treatments in the UK are a welcome development
Matthew Wood, Professor of Neuroscience in the Department of Paediatrics at the University of Oxford and Director & Chief Scientific Officer of the Oxford-Harrington Rare Disease Centre, comments on new government plans to bring treatments for rare diseases a step closer.
Last week the government announced new plans designed to speed up the development and approval of treatments for rare diseases, marking an important step forward for patients and families affected by life-limiting and currently untreatable conditions.
The reforms, announced by the Medicines and Healthcare products Regulatory Agency (MHRA), aim to create faster and more flexible pathways for innovative therapies, including personalised genetic medicines and RNA-based treatments. The announcement aligns closely with the mission of the Oxford-Harrington Rare Disease Centre, a pioneering partnership between the University of Oxford and the Harrington Discovery Institute in the United States, which works to accelerate the translation of scientific discoveries into treatments for rare diseases.
The Centre brings together researchers, clinicians, industry partners and patient groups to overcome the barriers that often prevent promising therapies from reaching patients with rare conditions.
Former UK Prime Minister Lord David Cameron, Chair of the Oxford-Harrington Rare Disease Centre Advisory Board, welcomed the announcement, highlighting the importance of international collaboration and innovation in tackling rare diseases.
Rare diseases affect around 3.5 million people in the UK, yet most conditions still have no approved treatment. Researchers developing therapies for these diseases often face significant scientific, regulatory and financial challenges, particularly because patient populations are small and clinical data can be limited.
The new MHRA framework aims to address these obstacles through more tailored regulatory approaches, greater use of NHS data and streamlined approval processes for highly specialised therapies.
Oxford researchers are already leading advances in genomics, gene therapy, precision medicine and clinical trials across a wide range of rare diseases, including neuromuscular disorders, rare cancers and inherited childhood conditions. The University is also a key partner in national and international rare disease initiatives focused on improving diagnosis, accelerating therapy development and expanding patient access to innovative treatments.
The government said the reforms would strengthen the UK’s position as a global leader in rare disease research and innovation, while helping more patients gain earlier access to potentially life-changing therapies.
The MHRA is currently seeking feedback on the framework from manufacturers, developers, clinicians, researchers, patient organisations, carers, families and other stakeholders. Further details of the new framework are expected to be published next year.
